Literature DB >> 11920334

Expression of glomerular plasminogen activator inhibitor type 1 in glomerulonephritis.

Kazumasa Hamano1, Masayuki Iwano, Yasuhiro Akai, Hiroaki Sato, Atsushi Kubo, Yoshiharu Nishitani, Hideto Uyama, Yukiko Yoshida, Masanobu Miyazaki, Hideo Shiiki, Shigeru Kohno, Kazuhiro Dohi.   

Abstract

Plasminogen activator inhibitor type 1 (PAI-1) and tissue plasminogen activator (tPA) are the major regulators of plasmin generation. Glomerular PAI-1/tPA balance is involved in extracellular matrix turnover, as well as fibrin deposition in glomeruli. Renal biopsy specimens were obtained from 80 patients with either primary or secondary glomerulonephritis (10 patients, minimal change nephrotic syndrome; 6 patients, focal segmental glomerulosclerosis [FSGS]; 10 patients, membranous nephropathy [MN]; 24 patients, mesangial proliferative glomerulonephritis; 15 patients, lupus nephritis; 14 patients, diabetic nephropathy; and 1 patient, membranoproliferative glomerulonephritis). We quantified glomerular PAI-1 and tPA messenger RNA (mRNA) by competitive polymerase chain reaction. We also determined PAI-1 mRNA localization by in situ hybridization. Glomerular PAI-1 mRNA levels in patients with FSGS and MN were significantly greater than those of controls. There was a sixfold increase in PAI-1-tPA mRNA ratio in patients with MN compared with the control group. In addition, glomerular PAI-1 mRNA level correlated with level of proteinuria. Conversely, there was no difference in tPA mRNA levels among types of glomerulonephritis. These results suggest that suppressed glomerular fibrinolytic and proteolytic activity may be associated with the pathogenesis of glomerulonephritis, especially in FSGS and MN. Copyright 2002 by the National Kidney Foundation, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11920334     DOI: 10.1053/ajkd.2002.31986

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  16 in total

1.  Venous thromboembolism in patients with membranous nephropathy.

Authors:  Sophia Lionaki; Vimal K Derebail; Susan L Hogan; Sean Barbour; Taewoo Lee; Michelle Hladunewich; Allen Greenwald; Yichun Hu; Caroline E Jennette; J Charles Jennette; Ronald J Falk; Daniel C Cattran; Patrick H Nachman; Heather N Reich
Journal:  Clin J Am Soc Nephrol       Date:  2011-11-10       Impact factor: 8.237

2.  Protease nexin-1, tPA, and PAI-1 are upregulated in cryoglobulinemic membranoproliferative glomerulonephritis.

Authors:  Sekiko Taneda; Kelly L Hudkins; Anja S Mühlfeld; Jolanta Kowalewska; Jeffrey W Pippin; Stuart J Shankland; Charles E Alpers
Journal:  J Am Soc Nephrol       Date:  2008-01-16       Impact factor: 10.121

Review 3.  New era for drug discovery and development in renal disease.

Authors:  Toshio Miyata; Katsushi Kikuchi; Hideyasu Kiyomoto; Charles van Ypersele de Strihou
Journal:  Nat Rev Nephrol       Date:  2011-07-05       Impact factor: 28.314

4.  Podocyte injury-driven intracapillary plasminogen activator inhibitor type 1 accelerates podocyte loss via uPAR-mediated β1-integrin endocytosis.

Authors:  Namiko Kobayashi; Toshiharu Ueno; Kumi Ohashi; Hanako Yamashita; Yukina Takahashi; Kazuo Sakamoto; Shun Manabe; Satoshi Hara; Yasutoshi Takashima; Takashi Dan; Ira Pastan; Toshio Miyata; Hidetake Kurihara; Taiji Matsusaka; Jochen Reiser; Michio Nagata
Journal:  Am J Physiol Renal Physiol       Date:  2015-01-13

5.  Risk factors for predicting venous thromboembolism in patients with nephrotic syndrome: focus on haemostasis-related parameters.

Authors:  Gener Ismail; Gabriel Mircescu; Alecse Valerian Ditoiu; Beatrice Dorina Tacu; Roxana Jurubita; Mihai Harza
Journal:  Int Urol Nephrol       Date:  2014-04       Impact factor: 2.370

6.  Plasminogen activator inhibitor-1 is a transcriptional target of the canonical pathway of Wnt/beta-catenin signaling.

Authors:  Weichun He; Ruoyun Tan; Chunsun Dai; Yingjian Li; Dan Wang; Sha Hao; Michael Kahn; Youhua Liu
Journal:  J Biol Chem       Date:  2010-06-02       Impact factor: 5.157

7.  A molecular signature of proteinuria in glomerulonephritis.

Authors:  Heather N Reich; David Tritchler; Daniel C Cattran; Andrew M Herzenberg; Felix Eichinger; Anissa Boucherot; Anna Henger; Celine C Berthier; Viji Nair; Clemens D Cohen; James W Scholey; Matthias Kretzler
Journal:  PLoS One       Date:  2010-10-18       Impact factor: 3.240

8.  Impact of the -675 4G/5G polymorphism of the plasminogen activator inhibitor-1 gene on childhood IgA nephropathy.

Authors:  Su-Ryun Han; Cheon-Jong Kim; Byung-Cheol Lee
Journal:  Exp Ther Med       Date:  2012-01-30       Impact factor: 2.447

Review 9.  The role of plasminogen activator inhibitor 1 in renal and cardiovascular diseases.

Authors:  Hunjoo Ha; Eun Y Oh; Hi B Lee
Journal:  Nat Rev Nephrol       Date:  2009-04       Impact factor: 28.314

Review 10.  Angiotensin II and progressive renal insufficiency.

Authors:  Jens Gaedeke; Nancy A Noble; Wayne A Border
Journal:  Curr Hypertens Rep       Date:  2002-10       Impact factor: 5.369

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.